On November 19, Connoya announced that the company's core product Claudin 18.2 antibody-conjugated drug CMG901 biological product license application was accepted by the US Food and Drug Administration and was granted priority review. It is intended to be used for second-line and subsequent treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with an expression ratio of at least 25% of tumor cells, covering about 60% of patients with gastric cancer/GEJ cancer. CMG901 is the first CLDN18.2 ADC to submit a new drug marketing application globally. The target review completion date for this BLA is expected to be in the second quarter of 2027.

Zhitongcaijing · 2d ago
On November 19, Connoya announced that the company's core product Claudin 18.2 antibody-conjugated drug CMG901 biological product license application was accepted by the US Food and Drug Administration and was granted priority review. It is intended to be used for second-line and subsequent treatment of patients with locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with an expression ratio of at least 25% of tumor cells, covering about 60% of patients with gastric cancer/GEJ cancer. CMG901 is the first CLDN18.2 ADC to submit a new drug marketing application globally. The target review completion date for this BLA is expected to be in the second quarter of 2027.